Rocket Pharmaceuticals Inc (RCKT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.37 (-3.71%), Market cap $0.40B, 52-week low–high $2.33 ~ $7.04.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of
Financial statements, price targets, institutional (13F) holdings and related news for Rocket Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Rocket Pharmaceuticals Inc trades at $3.37 (-3.71%). Real-time quotes and charts are available on BlackAll Trade.
Rocket Pharmaceuticals Inc has a market cap of about $0.40B.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and de